Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4947)
All Articles published online
|
Publishing Process of This Article
|
Aug 24, 2020 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Khetani VV, Portal DE, Shah MR, Mayer T, Singer EA. Combination drug regimens for metastatic clear cell renal cell carcinoma. World J Clin Oncol 2020; 11(8): 541-562 [PMID: 32879843 DOI: 10.5306/wjco.v11.i8.541] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v11/i8/541.htm |
| Number | Citing Articles |
| 1 |
Stefan Mrdenovic, Yanping Wang, Lijuan Yin, Gina Chia-Yi Chu, Yan Ou, Michael S. Lewis, Marija Heffer, Edwin M. Posadas, Haiyen E. Zhau, Leland W. K. Chung, Mouad Edderkaoui, Stephen J. Pandol, Ruoxiang Wang, Yi Zhang. A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer models. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-10878-3
|
| 2 |
Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola J. Lawrence, Robert Motzer, Bradley McGregor, Richard J. Lee, Rohit K. Jain, Nancy Davis, Leonard J. Appleman, Oscar Goodman, Walter M. Stadler, Sunil Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begoña Mellado, Juan Manuel Sepúlveda Sánchez, Robert Figlin, Thomas Powles, Lalith Akella, Keith Orford, Bernard Escudier. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology 2022; 8(10): 1411 doi: 10.1001/jamaoncol.2022.3511
|
| 3 |
Pedro Caetano Pinto, Cindy Rönnau, Martin Burchardt, Ingmar Wolff. Kidney Cancer and Chronic Kidney Disease: Too Close for Comfort. Biomedicines 2021; 9(12): 1761 doi: 10.3390/biomedicines9121761
|
| 4 |
Jeanny B Aragon-Ching. Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer. Future Medicinal Chemistry 2022; 14(11): 767 doi: 10.4155/fmc-2021-0301
|
| 5 |
Yize Li, Tung-Shing M. Lih, Saravana M. Dhanasekaran, Rahul Mannan, Lijun Chen, Marcin Cieslik, Yige Wu, Rita Jiu-Hsien Lu, David J. Clark, Iga Kołodziejczak, Runyu Hong, Siqi Chen, Yanyan Zhao, Seema Chugh, Wagma Caravan, Nataly Naser Al Deen, Noshad Hosseini, Chelsea J. Newton, Karsten Krug, Yuanwei Xu, Kyung-Cho Cho, Yingwei Hu, Yuping Zhang, Chandan Kumar-Sinha, Weiping Ma, Anna Calinawan, Matthew A. Wyczalkowski, Michael C. Wendl, Yuefan Wang, Shenghao Guo, Cissy Zhang, Anne Le, Aniket Dagar, Alex Hopkins, Hanbyul Cho, Felipe da Veiga Leprevost, Xiaojun Jing, Guo Ci Teo, Wenke Liu, Melissa A. Reimers, Russell Pachynski, Alexander J. Lazar, Arul M. Chinnaiyan, Brian A. Van Tine, Bing Zhang, Karin D. Rodland, Gad Getz, D.R. Mani, Pei Wang, Feng Chen, Galen Hostetter, Mathangi Thiagarajan, W. Marston Linehan, David Fenyö, Scott D. Jewell, Gilbert S. Omenn, Rohit Mehra, Maciej Wiznerowicz, Ana I. Robles, Mehdi Mesri, Tara Hiltke, Eunkyung An, Henry Rodriguez, Daniel W. Chan, Christopher J. Ricketts, Alexey I. Nesvizhskii, Hui Zhang, Li Ding, Alicia Francis, Amanda G. Paulovich, Andrzej Antczak, Anthony Green, Antonio Colaprico, Ari Hakimi, Barb Pruetz, Barbara Hindenach, Birendra Kumar Yadav, Boris Reva, Brenda Fevrier-Sullivan, Brian J. Druker, Cezary Szczylik, Charles A. Goldthwaite, Chet Birger, Corbin D. Jones, Daniel C. Rohrer, Darlene Tansil, David Chesla, David Heiman, Elizabeth Duffy, Eri E. Schadt, Francesca Petralia, Gabriel Bromiński, Gabriela M. Quiroga-Garza, George D. Wilson, Ginny Xiaohe Li, Grace Zhao, Yi Hsiao, James Hsieh, Jan Lubiński, Jasmin Bavarva, Jasmine Huang, Jason Hafron, Jennifer Eschbacher, Jennifer Hon, Jesse Francis, John Freymann, Josh Vo, Joshua Wang, Justin Kirby, Kakhaber Zaalishvili, Karen A. Ketchum, Katherine A. Hoadley, Ki Sung Um, Liqun Qi, Marcin J. Domagalski, Matt Tobin, Maureen Dyer, Meenakshi Anurag, Melissa Borucki, Michael A. Gillette, Michael J. Birrer, Michael M. Ittmann, Michael H. Roehrl, Michael Schnaubelt, Michael Smith, Mina Fam, Nancy Roche, Negin Vatanian, Nicollette Maunganidze, Olga Potapova, Oxana V. Paklina, Pamela VanderKolk, Patricia Castro, Paweł Kurzawa, Pushpa Hariharan, Qin Li, Qing Kay Li, Rajiv Dhir, Ratna R. Thangudu, Rebecca Montgomery, Richard D. Smith, Sailaja Mareedu, Samuel H. Payne, Sandra Cerda, Sandra Cottingham, Sarah Haynes, Shankha Satpathy, Shannon Richey, Shilpi Singh, Shirley X. Tsang, Shuang Cai, Song Cao, Stacey Gabriel, Steven A. Carr, Tao Liu, Thomas Bauer, Toan Le, Xi S. Chen, Xu Zhang, Yvonne Shutack, Zhen Zhang. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell 2023; 41(1): 139 doi: 10.1016/j.ccell.2022.12.001
|
| 6 |
Daniel M. Geynisman, Jodi K. Maranchie, Mark W. Ball, Gennady Bratslavsky, Eric A. Singer. A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer. Urologic Oncology: Seminars and Original Investigations 2021; 39(9): 548 doi: 10.1016/j.urolonc.2021.04.038
|
| 7 |
Christian U. Blank, Deborah J. Wong, Thai H. Ho, Todd M. Bauer, Carrie B. Lee, Fabiola Bene-Tchaleu, Jing Zhu, Xiaosong Zhang, Edward Cha, Mario Sznol. Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Current Oncology 2021; 28(6): 5466 doi: 10.3390/curroncol28060455
|
| 8 |
Li Tao, Huiyun Zhang, Guangyu An, Haoning Lan, Yaoqi Xu, Yang Ge, Jiannan Yao. Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.739263
|
| 9 |
Grace Lee, Brian M. Shinder, Evita Sadimin, Ryan D. Stephenson, Eric A. Singer. Diagnostic Molecular Pathology. 2024; : 447 doi: 10.1016/B978-0-12-822824-1.00035-3
|
| 10 |
Lichen Zhang, Deqiong Xie, Yonghua Lei, Aoli Na, Lei Zhu. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma. Future Oncology 2021; 17(23): 3051 doi: 10.2217/fon-2021-0256
|
| 11 |
Sai Krishnaraya Doppalapudi, Alain Kaldany, Benjamin Lichtbroun, Eric A. Singer. Handbook of Cancer and Immunology. 2023; : 1 doi: 10.1007/978-3-030-80962-1_232-1
|
| 12 |
Yongqiang Huang, Hong Sun, Pu Guo. Research Progress of Tumor Microenvironment Targeted Therapy for Clear Cell Renal Cell Carcinoma. Cancer Control 2023; 30: 107327482311557 doi: 10.1177/10732748231155700
|
| 13 |
Sai Krishnaraya Doppalapudi, Zev R. Leopold, Akshay Thaper, Alain Kaldany, Kevin Chua, Hiren V. Patel, Arnav Srivastava, Eric A. Singer. Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC. Cancers 2021; 13(16): 4140 doi: 10.3390/cancers13164140
|
| 14 |
Jiaming Su, Lu Zhou, Zhe Zhang, Xue Xiao, Yanning Qin, Xiaoying Zhou, Tingting Huang. The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1146738
|
| 15 |
Baltazar Eduardo Lema, García Marchiñena Patricio, Erica Lorena Kreimann. Nuclear expression of NHERF1/EBP50 in Clear Cell Renal Cell Carcinoma. Acta Histochemica 2021; 123(5): 151717 doi: 10.1016/j.acthis.2021.151717
|
| 16 |
Eleonora Pinto, Rita Alfieri, Luisa Orrù, Marta Silvia Dalla Riva, Gian Piero Turchi. Forward to a methodological proposal to support cancer patients: the dialogics’ contribution for the precision care. Medical Oncology 2022; 39(5) doi: 10.1007/s12032-021-01644-1
|